



Correction to: LUHMES Dopaminergic Neurons are Uniquely Susceptible to Ferroptosis

Zhi-Bin Tong¹ · Hyunhee Kim¹ · Lara El Touny¹ · Anton Simeonov¹ · David Gerhold¹

Published online: 27 August 2022

© Springer Science+Business Media, LLC, part of Springer Nature 2022

Correction to: Neurotoxicity Research

<https://doi.org/10.1007/s12640-022-00538-y>

The original article has been corrected in the Materials and Methods section:

“Ten millimolars of stock solutions was prepared” should be “Ten millimolar stock solutions were prepared”

“differentiated in an Advanced DMEM medium with 1 ug/ml tetracycline, 1 mM cAMP,” should be “differentiated in Advanced DMEM medium with 1 µg/ml tetracycline, 1 µM cAMP,”.

“poly-L-ornithine and human fibronectin (50 mg/ml each)” should be “poly-L-ornithine and human fibronectin (50 µg/ml each)”.

“Cells were treated for 24 h,” should be “Cells were treated with toxicants for 24 h,”.

“30 ml CellTitreGlo[®]” should be “30 µl per well CellTitreGlo[®]”.

“in quadruplicate for Figs.” should be “in triplicate for Figs.”.

“Hoechst 3342” should be “Hoechst 33342”.

“plus Hoechst 33342” should be “plus Hoechst 33342”.

The original article has been corrected in the Results section:

“than 1 mM, compared to ~20 mM for undifferentiated LUHMES and greater than 100 mM for” should be “than 1 µM, compared to ~20 µM for undifferentiated LUHMES and greater than 100 µM for”.

“Five millimolars of ferrostatin-1 markedly” should be “Five micromolar ferrostatin-1 markedly”.

“value from 0.29 mM using erastin alone to > 10 mM” should be “value from 0.29 µM using erastin alone to > 10 µM”.

“Five millimolars of ferrostatin-1 also” should be “Five micromolar ferrostatin-1 also”.

“living cells if 5 mM ferrostatin-1” should be “living cells if 5 µM ferrostatin-1”.

In Fig. 2a, x-axis labels “µM”, and Fig. 2b and -2c, “nM” and “nM”, and c should be in brackets; Fig. 2a, x-axis labels should be “[µM]”, and Fig. 2b and -2c, “[nM]” and “[nM]”.

Figure 2 legend “at 5 mM, b ML210 ± ferrostatin-1 at 5 mM, c RSL3 ± ferrostatin-1 at 5 mM” should be “at 5 µM, b ML210 ± ferrostatin-1 at 5 µM, c RSL3 ± ferrostatin-1 at 5 µM.”.

Figure 2 legend “ferrostatin-1, 5 mM. Nuclei” should be “ferrostatin-1 at 5 µM. Nuclei”.

“In Fig. 3a, b and c, x-axis labels “nM”, should be in brackets; “[nM]”.

“DFX 10 mM, DMPS 50 mM, and, to a lesser degree, DFP 50 mM” should be “DFX 10 µM, DMPS 50 µM, and, to a lesser degree, DFP 50 µM”.

“Glutathione 50 mM, a weak chelator” should be “Glutathione 50 µM, a weak chelator”.

“M30 was not toxic alone at 2.5 mM,” should be “M30 was not toxic alone at 2.5 µM,”.

In Fig. 4a, b and c, x-axis labels “µM”, should be in brackets; “[µM]”.

In Fig. 5 legend: “toxicants and 5 mM ferrostatin-1” should be “toxicants and 5 µM ferrostatin-1”.

In Fig. 5 legend: “(5 mM, black bars)” should be “(5 µM, black bars)”.

“those of neighboring astrocytes” should be “those in neighboring astrocytes”.

In Fig. 6 legend: “DFP 10 mM; M30 2.5 mM; glutathione, GSH 50 mM; desferrioxamine, DFX 50 mM; or 2,3-dimercapto-1-propanesulfonic acid, DMPS 50 mM” should be “DFP 10 µM; M30 2.5 µM; glutathione, GSH

The original article can be found online at <https://doi.org/10.1007/s12640-022-00538-y>.

✉ David Gerhold
david.gerhold@nih.gov

¹ Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA

50 mM; desferrioxamine, DFX 50 mM; or 2,3-dimercapto-1-propanesulfonic acid, DMPS 50 mM”.

The original article has been corrected in the Discussion section:

“rotenone, 6-hydroxydopamine, trimethyltin” should be “rotenone, 6-OHDA, trimethyltin”

“Parkinsonian toxicant 6-hydroxydopamine” should be “Parkinsonian toxicant 6-OHDA”.

“rotenone, 6-hydroxydopamine, and MPP,” should be “rotenone, 6-OHDA, and MPP,”.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.